Prognostic features for response and survival in elderly patients wth de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine

Leukemia and Lymphoma

Volumn 46, Issue 3, 2005, Pages 367-375

  Grigg, Andrew P ^a   Reynolds, J ^b   Mcquillan, A ^c   Juneja, S K ^a   Di Iulio, J ^b   Hui, C ^d   Smith, C ^e   Kimber, R ^f   Bradstock, K F ^g  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e AUSTIN HOSPITAL   (Australia)

^f ROYAL HOBART HOSPITAL   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

Author keywords

Cytarabine; Elderly AML; Mitoxantrone

Indexed keywords

CYTARABINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKEMIA REMISSION; MALE; MULTICENTER STUDY; MYELODYSPLASIA; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL TIME; TREATMENT PLANNING; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PATIENT SELECTION; PILOT PROJECTS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 13644258383     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400013076     Document Type: Article

References (37)

1. Menzin J, Lang K, Earle C, Kerney D, Mallick R. The outcome and costs of acute myeloid leukemia in the elderly. Arch Intern Med 2002;162:1597-1603.
2. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: assessment of multi-drug resistance (MDR) and cytogenetics distinguishes biological subgroups with remarkably distinct responses to standard chemotherapy: a Southwest oncology group study. Blood 1997;89:3323-3329.
3. Lowenberg B, Downing J, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062.
4. Delima M, Ghaddar H, Pierce S, Estey E. Treatment of newly diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996;93:89-93.
5. Baudard M, Marie J, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukemia in the elderly: retrospective study of 235 patients. Br J Haematol 1994;86:82-91.
6. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Teritan G, Desablens B, Henry-Amar M, Degos L. Low dose cytarabine versus intensive therapy in the treatment of acute non lymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272-279.
7. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Whatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older patients with acute myeloid leukemia (AML), analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98:1312-1320.
8. Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001;115:25.
9. Johnson P, Hunt L, Lin Yin J. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993;85:300-306.
10. LeMaistre CF, Herzig R. Mitoxantrone: potential for use in intensive therapy. Semin Oncol 1990;17:43-48.
11. Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K and the Lederle Cooperative Group. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990;4:177-183.
12. Liu Yin JA, Johnson PRE, Davies JM, Flanagan NG, Gorst DW, Lewis MJ. Mitozantrone and cytosine arabinoside as first line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991;79:415-420.
13. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC Jr, Beer M, Ahmed T. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 1997;11:485-489.
14. Gottlieb D, Bradstock K, Koutts J, Robertson T, Lee C, Castaldi P. The neurotoxicity of high-dose cytosine arabino-side is age-related. Cancer 1987;60:1439-1441.
15. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Shulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896.
16. Bishop JF, Matthews JP, Young GAR, Bradstock K, Low-enthal R on behalf of the ALSG. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315-327.
17. Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M, Champlin R. A randomised study of intermediate versus conventional dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol 1992;81:170-177.
18. Brito-Babapulle F, Catovsky D, Newland AC, Goldman JM, Galton DAG. Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Semin Oncol 1987;14:51-52.
19. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister A, LoCocco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
20. Gahn B, Haase D, Unterhalt M, Drescher M, Schoch C, Fonatsch C, Terstappen LW, Hiddemann W, Buchner T, Bennett JM, Wormann B. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia 1996;10:946-951.
21. Brunning RD, Matutes E, Harris NL, Flandrin G. Acute myeloid leukaemia with multilineage dysplasia. In: World Health Organization classification of tumours, pathology and genetics, tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p 88-89.
22. Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton, Florida: Chapman & Hall/CRC Press; 2003. p 97-106.
23. Lowenberg B, Sucieu S, Archimbaud E, Haak H, Stryckmans P, deCataldo R, Detter A, Berneman Z, Thycca A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Mitoxantrone versus daunorubicin in induction and consolidation therapy: the value of low dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Organisation for the Research and Treatment of Cancer and the Dutch Belgium Hemato-oncology cooperative Hovon group randomized phase III study AML-9. J Clin Oncol 1998;16:872-880.
24. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson M, Clark REl. Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311.
25. Kern Aul C, Maschmeyer G, Schronrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W for the German AML Cooperative Group. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 1998;12:1049-1055.
26. Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng Y-M, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11:2002-2009.
27. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiemik PH. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485.
28. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR, Bloomfield CD, Schiffer CA. Post-remission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate dose cytarabine with standard dose cytarabine. Blood 2001;98:548-553.
29. Anderson JE, Kopecky KJ, William CL, Head D, O'Donnell MR, Luthardt FW, Norwood TH, Chen I-M, Balcerzak SP, Johnson DB, Appelbaum FR. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002;100:3869-3876.
30. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GEG, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R on behalf of EORTC-LCG and HOVON. Use of recombinant granulocyte macrophage colony stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian hemato-oncology cooperative group (HOVON). Blood 1997;90:2952-2961.
31. Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, Fey M, Schouten H, de Greef G, Ferrant A, Kovacsovics T, Gratwohl A, Daenen S, Huijgens P, Boogaerts M for the Dutch-Belgian Hemato-Oncology (HOVON) Cooperative Group and the Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-752.
32. Roboz GJ, Knovich MA, Bayer RL, Schuster MW, Seiter K, Powell BL, Woodruff RD, Silver RT, Frankel AE, Feldman EJ. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 2002;43:1951-1955.
33. Larson RA, Boogaerts M, Estey E, Karanes E, Stadtmauer EA, Sievers EL, Mineru P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Applebaum FR, Mylotarg Study Group. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16:1627-1636.
34. Steins MB, Bieker R, Padro T, Kessler T, Kienast J, Berden WE, Mesters RM. Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma 2003;44:1489-1493.
35. Giles FJ, Garcia-Manera G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002;20:656-664.
36. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FRl. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031). Blood 1998;91:3607-3615.
37. Feinstein LC, Sandmaier BM, Hegenbart U, McSweeney PA, Maloney DG, Gooley TA, Maris MB, Chauncey TR, Bruno B, Appelbaum FR, Niederwieser DW, Storb RF. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003;120:281-288.